While the aforementioned evidence suggests that TCF7L2 mutation may impair proper pancreatic function and cognition, there is scarce literature deciphering the regulatory roles of TCF7L2 in APP-induced MetS. The gene discussed is TCF7L2; the disease is metabolic syndrome.